Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes

DOI10.1111/j.0006-341X.1999.00971.xzbMath1059.62717WikidataQ40712207 ScholiaQ40712207MaRDI QIDQ4666685

Nigel Stallard, Peter F. Thall, John Whitehead

Publication date: 13 April 2005

Published in: Biometrics (Search for Journal in Brave)

zbMATH Keywords

optimal stoppingbackward inductionsequential procedureclinical trial designsafety and efficacy minotoring

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian problems; characterization of Bayes procedures (62C10) Optimal stopping in statistics (62L15)

Related Items (10)

Bayesian designs and the control of frequentist characteristics: A practical solution ⋮ Bayesian techniques for sample size determination in clinical trials: a short review ⋮ Bayesian Optimal Design for Phase II Screening Trials ⋮ Bayesian predictive monitoring with bivariate binary outcomes in phase II clinical trials ⋮ Ethical issues in oncology biostatistics ⋮ Bayesian randomized clinical trials: A decision-theoretic sequential design ⋮ Computer science and decision theory ⋮ Decision-Theoretic Designs for Pre-Phase II Screening Trials in Oncology ⋮ Seamlessly Expanding a Randomized Phase II Trial to Phase III ⋮ Decision-Theoretic Designs for Phase II Clinical Trials Allowing for Competing Studies

Cites Work

• Unnamed Item
• Unnamed Item
• A Bayesian Approach to the Design of Phase II Clinical Trials
• One-Sided Sequential Stopping Boundaries for Clinical Trials: A Decision- Theoretic Approach
• Why Isn't Everyone a Bayesian?
• One-Sample Multiple Testing Procedure for Phase II Clinical Trials
• Group Sequential Clinical Trials: A Classical Evaluation of Bayesian Decision-Theoretic Designs
• Designs for Phase II Trials Allowing for a Trade-Off between Response and Toxicity
• Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials
• Sample Size Determination for Phase II Clinical Trials Based on Bayesian Decision Theory
• Practical Bayesian Guidelines for Phase IIB Clinical Trials
• A Sample-Size-Optimal Bayesian Procedure for Sequential Pharmaceutical Trials
• Bivariate Sequential Designs for Phase II Trials

This page was built for publication: Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes